Sean Harper, Stefan Scherer
Searching for new TCR targets, immunotherapy startup emerges with Stanford tech, $40M round
In the last decade, immunotherapy, which involves the usage of a patient’s own immune cells to fight cancers, has gained great momentum. In one variation …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
